A Phase III, Multicentre, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Safety of Once Daily Esomeprazole for the Treatment of Clinically Diagnosed Gastroesophageal Reflux Disease (GERD) in Pediatric and Adolescent Patients 12 to 17 Years of Age, Inclusive.
Phase of Trial: Phase III
Latest Information Update: 18 Nov 2009
At a glance
- Drugs Esomeprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 09 Sep 2008 New trial record.